Standout Papers
- [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study (2018)
- Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes (2018)
Immediate Impact
1 from Science/Nature 58 standout
Citing Papers
Prostate Cancer
2025 Standout
Radiopharmaceuticals and their applications in medicine
2025 Standout
Works of Mark Scalzo being referenced
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study
2018 Standout
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes
2018 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Mark Scalzo | 1034 | 1061 | 389 | 9 | 1.3k | |
| Aravind Ravi Kumar | 1168 | 1155 | 456 | 22 | 1.5k | |
| Ingo Klette | 802 | 1030 | 437 | 15 | 1.3k | |
| Germo Gericke | 1060 | 980 | 535 | 6 | 1.5k | |
| Nitin Vaishampayan | 1081 | 988 | 542 | 12 | 1.6k | |
| Stefan Kürpig | 1012 | 1122 | 452 | 23 | 1.3k | |
| Sue Ping Thang | 1238 | 1183 | 544 | 25 | 1.6k | |
| Christoph A. Umbricht | 678 | 936 | 323 | 15 | 1.1k | |
| Chandler H. Park | 1083 | 989 | 570 | 20 | 1.5k | |
| Euloge Kpamegan | 1259 | 1010 | 572 | 11 | 1.7k | |
| Anna Yordanova | 1115 | 1199 | 657 | 35 | 1.6k |
All Works
Loading papers...